Japan’s Ministry of Health, Labor and Welfare has extended Hemlibra (emicizumab)’s approval to include routine prophylaxis to prevent or lower the frequency of bleeds in people with acquired hemophilia A. Its decision comes seven months after Hemlibra’s maker, Chugai Pharmaceutical, applied for extended use. Hemlibra was previously approved in…
Search results for:
When talking about hemophilia, women are often overlooked. This is because males are much more susceptible to hemophilia A and B, while most females only experience mild symptoms that allow them to lead a mostly normal life (although this is not the case with type C). Because of the mild symptoms,…
Qfitlia (fitusiran) is an RNA-based therapy that is approved to prevent or reduce the frequency of bleeds in patients with hemophilia A or B, with or without inhibitors. It is given via under-the-skin, or subcutaneous, injections that can be self-administered.
Bayer has entered into a three-year research partnership with the Children’s Hospital of Philadelphia to develop small molecule non-replacement therapies as a first-line and less burdensome oral treatment for hemophilia A and B. Hemophilia is caused by a lack of blood clotting factors or their faulty production,…
Symptoms of pain, anxiety, and depression generally increased with disease severity in people with hemophilia and were also associated with a lower quality of life, according to a recent survey involving patients, caregivers, and healthcare providers. While many surveyed individuals felt their pain was adequately addressed in the clinic, fewer…
Precision Biologic has announced an update of its Cryocheck Chromogenic Factor VIII assay, a test used to help diagnose and manage hemophilia A. The update, which is expected to be commercially available in the coming months, will ensure that the assay’s accuracy is not compromised by a new…
The ongoing Phase 1/2 Alta trial continues to show that a single infusion of SB-525, an investigational gene therapy, leads to stable and clinically relevant improvements in clotting factor VIII and marked reductions in the need for replacement therapy in patients with hemophilia A. This preliminary follow-up data…
One of the major hurdles people with hemophilia face is complying with their medication schedule — in particular, injecting themselves several times a week with clotting factor. MORE: Seven recommended books to learn more about hemophilia Clotting factor has a relatively short half-life (the time it takes for a person’s…
Life can change in a moment. Sometimes, all it takes is a phone call — that a loved one has passed away, that you’ve lost your job, or that you are free from cancer. Those moments often create core memories — highly emotional, significant experiences that have a lasting…